Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.
作者信息
Shaikh Saad
出版信息
Indian J Ophthalmol. 2008 May-Jun;56(3):259. doi: 10.4103/0301-4738.40380.
Abstract
摘要
相似文献
1
Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.
Indian J Ophthalmol. 2008 May-Jun;56(3):259. doi: 10.4103/0301-4738.40380.
2
Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
Acta Ophthalmol Scand. 2006 Dec;84(6):834-5. doi: 10.1111/j.1600-0420.2006.00779.x.
3
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Retina. 2006 Mar;26(3):275-8. doi: 10.1097/00006982-200603000-00004.
4
Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
Clin Exp Ophthalmol. 2006 Nov;34(8):802-3. doi: 10.1111/j.1442-9071.2006.01378.x.
5
Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.
Acta Ophthalmol. 2008 Sep;86(6):683-7. doi: 10.1111/j.1600-0420.2007.01042.x.
6
Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.
Can J Ophthalmol. 2007 Apr;42(2):335-6.
7
Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
Am J Ophthalmol. 2006 Oct;142(4):685-8. doi: 10.1016/j.ajo.2006.04.058.
8
Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Acta Ophthalmol Scand. 2007 May;85(3):340-1. doi: 10.1111/j.1600-0420.2006.00832.x.
9
Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization.
Acta Ophthalmol. 2008 Feb;86(1):115-6. doi: 10.1111/j.1600-0420.2007.00977.x. Epub 2007 Aug 2.
10
Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.
Clin Exp Ophthalmol. 2008 Jul;36(5):449-54.
引用本文的文献
1
Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.
Haematologica. 2025 May 1;110(5):1092-1104. doi: 10.3324/haematol.2024.286420. Epub 2024 Dec 19.
2
Laser therapy for retinopathy in sickle cell disease.
Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3.
3
Hemoglobinopathies: ocular manifestations in children and adolescents.
Ther Adv Ophthalmol. 2021 Jun 30;13:25158414211022882. doi: 10.1177/25158414211022882. eCollection 2021 Jan-Dec.
4
Gross anterior segment ischaemia following vitreoretinal surgery for sickle-cell retinopathy.
BMJ Case Rep. 2019 Jan 29;12(1):e227541. doi: 10.1136/bcr-2018-227541.
5
The past, present and future management of sickle cell retinopathy within an African context.
Eye (Lond). 2018 Aug;32(8):1304-1314. doi: 10.1038/s41433-018-0162-8. Epub 2018 Jul 10.
6
Inflammation in sickle cell disease.
Clin Hemorheol Microcirc. 2018;68(2-3):263-299. doi: 10.3233/CH-189012.
7
Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.
PLoS One. 2017 Aug 23;12(8):e0183320. doi: 10.1371/journal.pone.0183320. eCollection 2017.
8
Laser therapy for retinopathy in sickle cell disease.
Cochrane Database Syst Rev. 2015 Oct 9;2015(10):CD010790. doi: 10.1002/14651858.CD010790.pub2.
9
Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Haematologica. 2015 Jun;100(6):730-9. doi: 10.3324/haematol.2014.119727. Epub 2015 Mar 13.
10
Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report.
Case Rep Ophthalmol Med. 2014;2014:682583. doi: 10.1155/2014/682583. Epub 2014 Nov 23.
本文引用的文献
1
Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
Acta Ophthalmol Scand. 2006 Dec;84(6):834-5. doi: 10.1111/j.1600-0420.2006.00779.x.
Zotero 插件